Fate Therapeutics, Inc. (FATE) Fair Value 2026

FATE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-28, Fate Therapeutics, Inc. (FATE) trades at $2.43. QOC: 5.6/10. Value Trap Risk: 43/100 (WARN). 1/13 models active.

Key Facts

Ticker
FATE
Price
$2.43
Quality Score
5.6/10
Value Trap Risk
43/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give FATE?

1 Intrinsic Value Models vs. Current Price ($2.43)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.77 -27.2%

All Models Active

All 1 models are displayed above.

What Is Fate Therapeutics, Inc. (FATE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Fate Therapeutics, Inc.'s intrinsic value is estimated at $1.77. Trading at its current price of $2.43, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -27.2%.

What Do the Models Say About FATE?

1 of 13 models are currently active for FATE. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does FATE Rank in Biotechnology?

Among 625 Biotechnology stocks, FATE ranks #200 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Fate Therapeutics, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is FATE a Value Trap?

CirclFi's Value Trap algorithm assigns FATE a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Fate Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Fate Therapeutics, Inc. earns a quality score of 5.6/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FATE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FATE's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Fate Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CYCNCyclerion Therapeutics, Inc.QOC 5.6ALTAltimmune, Inc.QOC 5.6AUTLAutolus Therapeutics plcQOC 5.6SCNIScinai Immunotherapeutics Ltd.QOC 5.6UPBUpstream Bio, Inc.QOC 5.6ACETAdicet Bio, Inc.QOC 5.6DFTXDefinium Therapeutics, Inc.QOC 4.9BHVNBiohaven Ltd.QOC 4.2ABUSArbutus Biopharma CorporationQOC 7.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CYCN · ALT · AUTL · SCNI · UPB · ACET · DFTX · BHVN · ABUS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to FATE?

7 companies across all industries closest to FATE’s Quality of Company score of 5.6/10.

KLARKlarna Group plcQOC 5.6TMDETMD Energy LimitedQOC 5.6LFWDLifeward Ltd.QOC 5.6MWYNMarwynn Holdings, Inc.QOC 5.6NNOXNano-X Imaging Ltd.QOC 5.6LIQTLiqTech International, Inc.QOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KLAR · TMDE · LFWD · MWYN · NNOX · LIQT · NVDA

Where Does FATE Sit in CirclFi's Biotechnology Rankings?

FATE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Fate Therapeutics, Inc.’s Valuation?

What is Fate Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Fate Therapeutics, Inc. (FATE). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FATE overvalued or undervalued right now?

At $2.43, 0 of 1 active models suggest FATE may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Fate Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.6 mean for FATE?

Fate Therapeutics, Inc.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on FATE?

CirclFi analyzes FATE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is FATE a value trap in 2026?

Fate Therapeutics, Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Fate Therapeutics, Inc. (FATE) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/FATE/ · Methodology
Primary sources for this FATE valuation
  • Financial statements: Fate Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001434316) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for FATE as of ; valuations recomputed .